New drug cocktail aims to shrink aggressive breast tumors before surgery
NCT ID NCT07371208
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial is testing a combination of two drugs—Sac-TMT (a targeted chemotherapy) and KL-A167 (an immunotherapy)—given before surgery to 40 people with triple-negative breast cancer. The goal is to see if the combo can eliminate or shrink tumors enough to improve long-term outcomes. Participants will receive the drugs for 12 to 24 weeks, then have surgery to assess response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacituzumab tirumotecan (Sac-TMT) and KL-A167 (a PD-L1 inhibitor)
What this could lead to
If successful, this combination could shrink tumors before surgery, potentially improving outcomes for people with triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial (40 people) with no control group, so results may not apply broadly. Side effects from the drug combination are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••